Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: A phase II trial (Digestive Diseases (2007) 25, (100-105) DOI: 10.1159/000099177);Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: A phase II trial (Retraction in: Digestive Diseases (2008) 26:2 (188))

Digestive Diseases

Volumn 25, Issue 1, 2007, Pages 100-105

  Souglakos, J ^a   Vardakis, N ^a   Androulakis, N ^a   Kakolyris, S ^a   Kourousis, C ^a   Mavroudis, D ^a   Pallis, A ^a   Agelaki, S ^a   Kalbakis, K ^a   Georgoulias, V ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

5 Fluorouracil; CPT 11 5 FU LV (AIO schedule); Irinotecan; Leucovorin; Metastatic colorectal cancer; Metastatic colorectal cancer, salvage treatment; Oxaliplatin

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; ATROPINE; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IRINOTECAN; LOPERAMIDE; OXALIPLATIN;

ABDOMINAL PAIN; AGED; ANALGESIA; ANEMIA; ANTIBIOTIC THERAPY; ARTICLE; ASTHENIA; BONE METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TREATMENT FAILURE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; INFECTION; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; SALVAGE THERAPY; SKIN INFECTION; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION;

EID: 33947602613     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000128588     Document Type: Erratum

References (19)

1. Black RJ, Bray F, Ferlay J, et al: Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer 1997;33:1075-107.
2. American Cancer Society: Cancer facts and figures - 2000. Atlanta, ACS, 2000.
3. The Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992;10:896-903.
4. Kohne CH, Schoffski P, Wilke H, et al: Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncol 1998;16:418-26.
5. Bleiberg H: Oxaliplatin: a new reality in colorectal cancer. Br J Cancer 1998;77(suppl 4):1S-3S.
6. Giacchetti S, Perpoint B, Zidani R, et al: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer J Clin Oncol 2000;18:136-147.
7. De Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947.
8. Cunningham D, Pyrhonen S, James R, et al: Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-1418.
9. Rougier P, van Cutsem E, Bajetta E, et al: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407-1412.
10. De Gramont A, Bosset JF, Milan C, et al: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol 1997;14:808-815.
11. Vanhoefer U, Harstrick A, Kohne CH, et al: Phase I study of a weekly schedule of irinotecan, high-dose leucovorin and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer. J Clin Oncol 1999;17:907-913.
12. Fischel JL, Rostagno P, Etienne MC, et al: Optimal combination between irinotecan, oxaliplatin and fluorouracil-folinic acid: experimental data on human colorectal cell lines. Proc Am Assoc Cancer Res 1999;40:589, abstr 3882.
13. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 1959;53:457-481.
14. Cox DR: The Analysis of Binary Data. London, Methnen, 1970.
15. Machover D, Diaz-Rubio E, de Gramont A, et al: Two consecutive phase II studies of oxaliplatin for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996;6:95-98.
16. Saltz LB, Douillard J, Pirotta N, et al: Combined analysis of two phase III randomized trials comparing irinotecan, flourouracil, leucovorin vs. flourouracil alone as first-line treatment of metastatic colorectal cancer. Proc Am Soc Clin Oncol 2000;19:242, abstr 938.
17. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomized trial. Lancet 2000;355:1041-1047.
18. Ulrich-Pur H, Kornek GV, Fiebiger W, et al: Multicenter phase II trial of dose fractionated irinotecan with advanced colorectal cancer failed oxaliplatin-based first-line combination chemotherapy. Ann Oncol 2001;12:1269-1272.
19. Tournigand C, Louvet C, Quinaux E, et al: FOLFIRI followed by FOLFOX vs. FOLFOX followed by FOLFIRI in metastatic colorectal cancer: final results of a phase III study. Proc Am Soc Clin Oncol 2001;20:124, abstr 494.